'Pretty striking': Pfizer results prompt calls for Australian investment in new technology

  • 📰 smh
  • ⏱ Reading Time:
  • 18 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 80%

Italia Notizia Notizia

Italia Ultime Notizie,Italia Notizie

Strong early results from Pfizer and BioNTech's phase 3 coronavirus vaccine trial have been welcomed by local vaccine experts, promoting renewed calls for Australia to invest in new types of vaccine manufacturing technology | MsEmmaK

She warned there were still key unknowns about the results, however, including how long the protection against the virus might last and whether some cohorts of trial participants may not be seeing benefits from the vaccine.

The Pfizer product, known as BNT162b2, has already been granted a provisional determination by Australia's Therapeutic Goods Administration, which paves the way for Pfizer to apply for a provisional registration of the product.and began this process on Monday. CSL will also make the University of Queensland's vaccine if it passes trials.

 

Grazie per il tuo commento. Il tuo commento verrà pubblicato dopo essere stato esaminato.

MsEmmaK Hang on, can you verify this story? Apparently 40K people with covid, 94 patients were chosen of which 8 received the vaccine (the others placebo). Before we start talking about a vaccine for billions of people let’s get a bit of perspective first.....

Abbiamo riassunto questa notizia in modo che tu possa leggerla velocemente. Se sei interessato alla notizia puoi leggere il testo completo qui. Leggi di più:

 /  🏆 6. in İT

Italia Ultime Notizie, Italia Notizie